Abstract
Myofibroblasts are associated with organ fibrosis, but their precise origin and functional role remain unknown. We used multiple genetically engineered mice to track, fate map and ablate cells to determine the source and function of myofibroblasts in kidney fibrosis. Through this comprehensive analysis, we identified that the total pool of myofibroblasts is split, with 50% arising from local resident fibroblasts through proliferation. The nonproliferating myofibroblasts derive through differentiation from bone marrow (35%), the endothelial-to-mesenchymal transition program (10%) and the epithelial-to-mesenchymal transition program (5%). Specific deletion of Tgfbr2 in α-smooth muscle actin (αSMA)+ cells revealed the importance of this pathway in the recruitment of myofibroblasts through differentiation. Using genetic mouse models and a fate-mapping strategy, we determined that vascular pericytes probably do not contribute to the emergence of myofibroblasts or fibrosis. Our data suggest that targeting diverse pathways is required to substantially inhibit the composite accumulation of myofibroblasts in kidney fibrosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
206,07 € per year
only 17,17 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout





Similar content being viewed by others
Change history
07 October 2013
In the version of this article initially published, the original panels intended for publication in Figure 2b were accidentally placed by the authors on top of other panels from a different experiment. As one of the overlapping images was semitransparent, the published imaged was the combination of two different micrographs. The error has been corrected in the HTML and PDF versions of the article.
References
Gabbiani, G. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200, 500–503 (2003).
Sugimoto, H., Mundel, T.M., Kieran, M.W. & Kalluri, R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 5, 1640–1646 (2006).
Meran, S. & Steadman, R. Fibroblasts and myofibroblasts in renal fibrosis. Int. J. Exp. Pathol. 92, 158–167 (2011).
Humphreys, B.D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85–97 (2010).
Lin, S.L., Kisseleva, T., Brenner, D.A. & Duffield, J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617–1627 (2008).
Rønnov-Jessen, L., Petersen, O.W., Koteliansky, V.E. & Bissell, M.J. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J. Clin. Invest. 95, 859–873 (1995).
Armulik, A., Genove, G. & Betsholtz, C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 21, 193–215 (2011).
Hall, A.P. Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. Toxicol. Pathol. 34, 763–775 (2006).
Iwano, M. et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110, 341–350 (2002).
Kalluri, R. & Neilson, E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112, 1776–1784 (2003).
Zeisberg, M. & Kalluri, R. Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis. Front. Biosci. 13, 6991–6998 (2008).
Zeisberg, M. & Kalluri, R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J. Mol. Med. 82, 175–181 (2004).
Li, J., Qu, X. & Bertram, J.F. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am. J. Pathol. 175, 1380–1388 (2009).
Zeisberg, E.M., Potenta, S.E., Sugimoto, H., Zeisberg, M. & Kalluri, R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282–2287 (2008).
Broekema, M. et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J. Am. Soc. Nephrol. 18, 165–175 (2007).
Li, J., Deane, J.A., Campanale, N.V., Bertram, J.F. & Ricardo, S.D. The contribution of bone marrow-derived cells to the development of renal interstitial fibrosis. Stem Cells 25, 697–706 (2007).
LeBleu, V.S. et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat. Med. 19, 227–231 (2013).
LeBleu, V. et al. Stem cell therapies benefit Alport syndrome. J. Am. Soc. Nephrol. 20, 2359–2370 (2009).
LeBleu, V.S., Sugimoto, H., Miller, C.A., Gattone, V.H. II & Kalluri, R. Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect induced Alport renal disease. Lab. Invest. 88, 284–292 (2008).
Leask, A. & Abraham, D.J. TGF-β signaling and the fibrotic response. FASEB J. 18, 816–827 (2004).
Chytil, A., Magnuson, M.A., Wright, C.V. & Moses, H.L. Conditional inactivation of the TGF-β type II receptor using Cre:Lox. Genesis 32, 73–75 (2002).
Ozerdem, U., Grako, K.A., Dahlin-Huppe, K., Monosov, E. & Stallcup, W.B. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn. 222, 218–227 (2001).
Bergers, G. & Song, S. The role of pericytes in blood-vessel formation and maintenance. Neuro-oncol. 7, 452–464 (2005).
Cooke, V.G. et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21, 66–81 (2012).
Díaz-Flores, L. et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol. Histopathol. 24, 909–969 (2009).
Hirschi, K.K. & D'Amore, P.A. Pericytes in the microvasculature. Cardiovasc. Res. 32, 687–698 (1996).
Lindahl, P., Johansson, B.R., Leveen, P. & Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B–deficient mice. Science 277, 242–245 (1997).
Song, S., Ewald, A.J., Stallcup, W., Werb, Z. & Bergers, G. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 7, 870–879 (2005).
Foo, S.S. et al. Ephrin-B2 controls cell motility and adhesion during blood-vessel–wall assembly. Cell 124, 161–173 (2006).
Abraham, S., Kogata, N., Fassler, R. & Adams, R.H. Integrin β1 subunit controls mural cell adhesion, spreading, and blood vessel wall stability. Circ. Res. 102, 562–570 (2008).
Kriz, W., Kaissling, B. & Le Hir, M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J. Clin. Invest. 121, 468–474 (2011).
Liu, Y. New insights into epithelial-mesenchyal transition in kidney fibrosis. J. Am. Soc. Nephrol. 21, 212–222 (2010).
Sugimoto, H. et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat. Med. 18, 396–404 (2012).
Collett, G.D. & Canfield, A.E. Angiogenesis and pericytes in the initiation of ectopic calcification. Circ. Res. 96, 930–938 (2005).
Hashimoto, N. et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 43, 161–172 (2010).
Zeisberg, E.M. et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13, 952–961 (2007).
Rock, J.R. et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl. Acad. Sci. USA 108, E1475–E1483 (2011).
Zeisberg, M. et al. BMP-7 counteracts TGF-β1–induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9, 964–968 (2003).
Tondreau, T. et al. Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential. Cytotherapy 6, 372–379 (2004).
Acknowledgements
This study was supported by US National Institutes of Health (NIH) grants DK55001, DK81976, CA125550, CA155370, CA163191 and CA151925 (all to R.K.). R.K. is supported by the Cancer Prevention and Research Institute of Texas and the Metastasis Research Center at MD Anderson Cancer Center. V.S.L. was funded by the NIH Research Training Grant in Gastroenterology (2T32DK007760-11), V.G.C. was funded by the US National Research Service Award (NRSA) F32 Ruth Kirschstein Post-doctoral Fellowship from the NIH (5F32DK082119-02). H.S. was funded by the NIH Research Training Grant in Cardiovascular Biology (5T32HL007374-30). J.O. was funded by the US Department of Defense Breast Cancer Research Predoctoral Traineeship Award (W81XWH-09-1-0008). G.T. was funded by the International Society of Nephrology Fellowship. C.W. was funded by the NIH Research Training Grant in Pediatric Nephrology (T32DK007726). Pdgfrb-Cre mice were kindly provided by R. Adams, Max Planck Institute for Molecular Biomedicine. γGT-Cre mice were kindly provided by E. Neilson, Northwestern University. Tgfbr2flox/flox mice were kindly provided by H. Moses, Vanderbilt University.
Author information
Authors and Affiliations
Contributions
R.K. provided the conceptual framework and intellectual input, designed the study and helped in the writing of the manuscript. V.S.L. designed the study, provided intellectual input, performed experiments, collected data and wrote the manuscript. V.S.L., G.T., Y.T., V.G.C., H.S., J.O. and C.W. performed some experiments and collected data. The data was analyzed by V.S.L., G.T., H.S. and C.W.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–6 and Supplementary Methods (PDF 879 kb)
Rights and permissions
About this article
Cite this article
LeBleu, V., Taduri, G., O'Connell, J. et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19, 1047–1053 (2013). https://doi.org/10.1038/nm.3218
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3218